The research in amino acid metabolism in AML is currently mostly focused on glutamine because it is a known vulnerability of AML cells, and specific inhibitors of GLS are reported to be safe and well tolerated in a Phase Ib/II clinical trial in patients with advanced myelodysplastic syndrome (68). The gene discussed is GLS; the disease is acute myeloid leukemia.